Portfolio Companies
 

CBI's extensive knowledge of the biopharmaceutical industry, investment expertise, strategic relationships including extensive network of academic and industry contacts all come together to successfully create a flourishing portfolio of biotechnology companies. These companies generate strong returns to their shareholders and are rapidly becoming leaders in their respective fields: from computational genomics and cancer detection and therapeutics through medical preparations for chronic wounds to selective drug targeting and delivery for the central nervous system.

Our unique strategy together with our strong resources assists our portfolio companies through the challenges of product and business development. We help recruit management executives and advisors, identify complementary technology and products, negotiate agreements, develop business strategies, and ensure successful follow-on financings.

Company Holdings Field Stage
Polyheal 35% Wound Healing Approved for marketing
MediWound 56% Severe Burns Phase III
D-Pharm 41% Ischemic Stroke Phase III
Andromeda 90% Type 1 Diabetes Phase III
CureTech 42% Cancer Phase II
BioCancell 27% Cancer Phase II
Apposense 4% Cancer, Stroke Phase II
Biokine 33% Cancer Phase I
BrainTact 24% Cancer, ALS PC
Thrombotech 40% Stroke PC
Campus Bio 100% Drug
Development
 
CLS 100% GMP Facility  

 

Andromeda
 

MediWound
 

D-Pharm
 

CureTech
 

BioCancell
 

Polyheal
 

Aposense
 

Biokine
 

Thrombotech
 

Braintact
 

CampusBio
 

CLS

     
 
Back To Top
   


  Home | Profile | Team | Portfolio | Contact Us | Disclaimer
All Rights Reserved to Clal Biotechnology Industries Ltd.